Navigation Links
TetraLogic Appoints Jonathan B. Lloyd Jones as Chief Financial Officer and Vice President Corporate Development
Date:6/8/2011

MALVERN, Pa., June 8, 2011 /PRNewswire/ -- TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced the appointment of Mr. Jonathan B. Lloyd Jones, ACA, MBA, as chief financial officer and vice president of corporate development.

Mr. Lloyd Jones joins TetraLogic with over 25 years of corporate development and finance experience.  He has led negotiations, valuation and diligence teams that developed and executed over $2 billion of biotechnology and pharmaceutical company mergers and acquisitions, financing and licensing transactions. At TetraLogic, Mr. Lloyd Jones will lead the company's corporate development and financing strategies as well as the negotiation and execution of related transactions.

From 2006 to 2010, Mr. Lloyd Jones served as vice president of finance at TransMolecular, Inc. During the prior 10 years, he was employed by Genzyme as a senior director of corporate development. Earlier in his career Mr. Lloyd Jones was employed by the Royal Bank of Scotland (Nassau). Mr. Lloyd Jones holds a master of business administration from The Wharton School of the University of Pennsylvania and is a member of the Institute of Chartered Accountants in England & Wales.

About TetraLogic Pharmaceuticals

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that focuses on the discovery and development of Smac mimetics, small molecule drugs that mimic Smac (Second mitochondrial-derived activator of caspases) for the treatment of cancers. The company's institutional investors include Clarus Ventures, HealthCare Ventures, Quaker BioVentures, Novitas Capital, Nextech Invest Ltd, Hatteras Venture Partners, Pfizer Ventures, Latterell Venture Partners, the Vertical Group, Amgen Ventures, and Kammerer Associates. For additional information, please refer to the company's Web site at

SOURCE TetraLogic Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. TetraLogic Closes $23 Million Second Tranche of Series C Financing
2. TetraLogic Closes $6 Million Series C-1 Investment with Nextech Invest Ltd.
3. Quark Pharmaceuticals Appoints New Chief Medical Officer
4. West Pharmaceutical Services, Inc. Appoints New Director
5. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
6. Curemark Appoints Preeminent Pediatrics Gastroenterologist
7. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
10. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
11. NovaRx Appoints Industry Veteran as President and COO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, ... PTN), a biopharmaceutical company developing targeted, receptor-specific peptide ... unmet medical need and commercial potential, today announced ... of 2,050,000 shares of its common stock and ... its common stock.  Funds under the management of ...
(Date:12/24/2014)... -- Echo Therapeutics, Inc. (NASDAQ: ECTE ... permeation, continuous glucose monitoring and associated technologies, today ... been appointed Chief Executive Officer effective December 22, ... of experience in the medical device, pharmaceutical and ... Vice President, Business Development, Otsuka Pharmaceuticals as well as ...
(Date:12/24/2014)... 24, 2014 LifeScienceIndustryResearch.com ... Disposable Syringe Industry of 178 pages providing ... intelligence library. The 2014 Market ... is a professional and deep research report ... analysis, the report introduces Disposable Syringe basic ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5
... Verinata Health, Inc., a privately-held company dedicated to maternal ... corporate headquarters and laboratory operations to 800 Saginaw Drive, ... a much larger and state-of-the art facility is a ... growth and expansion expected with the launch of our ...
... PITTSBURGH, Dec. 7, 2011 HealthpointCapital, LLC ("HealthpointCapital") ... Inc. ("Blue Belt" or "Company"). Blue Belt is ... for use initially in orthopedic procedures and then ... ("ENT"). Terms of the transaction were not disclosed. ...
Cached Medicine Technology:Verinata Health Announces New Corporate Headquarters and Expanded Laboratory Operations 2HealthpointCapital Acquires Blue Belt Technologies, Inc. and Appoints Eric B. Timko as President and CEO 2
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of ... its new selection of black one-shoulder cocktail dresses . ... they are available at discounted prices, up to 70% off. ... last for three weeks only. You know, we have thousands ... interested in our new items can visit our website for ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... with complex chronic illnesses can receive effective, less expensive care ... easy access to a team of dedicated health care professionals, ... become seriously ill and need either hospitalization or a trip ... enhanced medical home clinic at the University of Texas in ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... could be closing in on a "fountain of youth" drug ... health of older adults, a new study suggests. Seniors ... a drug that targets a genetic signaling pathway linked to ... report. The experimental medication, a version of ...
(Date:12/25/2014)... Plugin creators from Pixel Film Studios have ... business presentation tool made specifically for Final Cut ... tool, users can now display their stats and facts ... Studios. “ProFire 5k gives users a multiple options to ... a presentation” , Pixel Film Studios takes the heat ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... estrogen therapy does not decrease, but may increase, the ... studies have reported an association between postmenopausal estrogen use ... of estrogen or estrogen plus progestin in women aged ... dementia. In the estrogen-only trial, researchers found 47 participants ...
... the body. Parkinson's patients are particularly at risk for ... a drug commonly used to treat the disease, produces ... patients with Parkinson’s disease who have high levels of ... worse cognitive functioning than other patients who have normal ...
... about 40 milligrams of vitamin C daily as new ... may protect against rheumatoid arthritis. ,Researchers studied 23,000 ... 74. Participants' diets were assessed by using seven-day-food-intake diaries.It ... or more joints for at least one month and ...
... symptoms of rheumatoid arthritis as well as keep cardiovascular ... have an anti-inflammatory effect and are well-known for reducing ... puts sufferers at an increased risk of cardiovascular disease. ... day of atorvastatin or a placebo in addition to ...
... testicles and cause prostate cancer cells to grow. Lowering ... grow more slowly. However, hormone therapy will not cure ... such as surgery or radiation are not good options. ... cancer significantly increases the risk of fractures.For the study ...
... be risking bone loss say researchers. Investigators tested post-menopausal women ... likely to have lower scores on heel and hip tests ... ,More than 6,000 women participated in the study.The loss ... both the heel bone and the hip. Those numbers held ...
Cached Medicine News:
The AGC Revision Knee, extends the AGC Family to include implants for severe primary knees or revision. Provides rotational freedom of +/- 2 and varus/valgus freedom of +/- 1.5....
... been shown to produce the highest contact ... fixed bearing component. This combination of high ... loading minimizes the risk of polyethylene deterioration ... symmetrical component design streamlines inventory requirements without ...
The Advance revision knee system was designed to address the unpredictable nature of revision knee arthroplasty by providing a wide variety of implant and instrument options....
The AGC dual articular knee is indicated for severe primary or revision cases and features a patented unique articulation which allows controlled rotation of the femoral component about a central piv...
Medicine Products: